A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination with Anti-cancer Agents in Adult Participants with Tumours Harbouring a KRASG12D Mutation

Trial Identifier: D7080C00001
Sponsor: AstraZeneca
Start Date: October 2024
Primary Completion Date: October 2025
Study Completion Date: June 2026
Condition: Cancer - Other; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
JP Tokyo, JP, 104-0045
KR Seoul, KR, 03080
US, CA Duarte, CA, US, 91010
US, NY New York, NY, US, 10016
US, VA Fairfax, VA, US, 22031